ETFIQData as of Nov 18, 2026. · etfiq.com/funds/xmmoDownload PDF

XMMO Fact Sheet: Invesco S&P MidCap Momentum ETF

Share
$130.99
close, Nov 18, 2026

Over the year to Nov 18, 2026, XMMO returned −0.3% in total and charged 0.34% a year.

1-year total return
−0.3%
to Nov 18, 2026
Expense ratio
0.34%
a year
Net assets
$6.1bn
on Nov 17, 2026
Net flow, last 5 trading days
−$87.0m
daily basis to Nov 17, 2026

Growth of $10,000, 1 year

XMMO $9,967 −0.3% · Total return, distributions reinvested, Nov 18, 2025 to Nov 18, 2026.

Returns

WindowTotal return
1 month−6.8%
3 months−17.7%
Year to date−4.9%
1 year−0.3%
3 years+61.6%
5 years+43.8%

Total return, distributions reinvested, each window to Nov 18, 2026.

Ten largest positions

HoldingWeight
Roivant Sciences Ltd4.28%
TechnipFMC PLC4.16%
ATI Inc4.12%
United Therapeutics Corp2.72%
Jazz Pharmaceuticals PLC2.69%
MKS Inc2.59%
TD SYNNEX Corp2.56%
HF Sinclair Corp2.56%
BrightSpring Health Services Inc2.42%
Reliance Inc2.24%

XMMO top ten by weight, 30.3% of the fund, of its 79 equity positions, from the holdings published by its issuer for Nov 17, 2026.

Facts

Equity fund · Tracks the S&P MidCap 400 Momentum Index · First traded Mar 3, 2005 · Benchmark Its own holdings, as of Nov 17, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, XMMO Fact Sheet: Invesco S&P MidCap Momentum ETF. Data as of Nov 18, 2026. https://etfiq.com/funds/xmmo/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/xmmo.